Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 77 clinical trials
Featured trial
Pacific 4: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.

  • 0 views
  • 26 Aug, 2022
  • 1 location
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a

EGFR
gilbert's syndrome
carboplatin
metastasis
neutrophil count
  • 37 views
  • 10 Jul, 2022
  • 12 locations
  • 11 views
  • 10 Aug, 2022
  • 208 locations
  • 208 views
  • 22 Sep, 2022
  • 165 locations
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

response with JNJ-61186372 and lazertinib combination in participants with EGFR Exon19del or L858R mutated NSCLC progressed on or after osimertinib (Phase 1b expansion Cohort D).

cancer chemotherapy
tyrosine
platinum-based chemotherapy
EGFR
lung carcinoma
  • 10 views
  • 24 Jul, 2022
  • 78 locations
Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI

This is a prospective, randomised, positive-controlled, study to assess the neurocognitive function of upfront Osimertinib compared to whole-brain irradiation (WBI) plus Osimertinib in EGFR

  • 0 views
  • 11 Apr, 2021
  • 1 location
Reqorsa (Quaratusugene Ozeplasmid) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (Acclaim-1)

The purpose of this randomized study is to determine the safety and efficacy of Reqorsa (quaratusugene ozeplasmid, formerly known as GPX-001) added to osimertinib in NSCLC patients with

EGFR
kidney function test
cancer chemotherapy
advanced lung cancer
lung carcinoma
  • 0 views
  • 11 Aug, 2022
  • 5 locations
Osimertinib In EGFR Mutant Lung Cancer

is: Osimertinib (Tagrisso)

EGFR
follicle stimulating hormone
lung carcinoma
stage iv non-small cell lung cancer
targeted therapy
  • 3 views
  • 25 Jul, 2022
  • 2 locations
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases (OUTRUN)

20-40% of patients with NSCLC will develop brain metastases at some point during their course of disease. Osimertinib has demonstrated intracranial activity in EFGR mutated NSCLC with

  • 64 views
  • 19 Feb, 2022
  • 10 locations
Gene Profile in EGFRm Locally Advanced or Metastatic NSCLC Patients Post Osimertinib 1L Treatment Failure: A Real-world, Multi-center Study (GPS) (GPS)

Although some small sample studies have reported the possible resistance mechanisms of Osimertinib in the first-line treatment, it is still an urgent need to explore the whole gene profile in

  • 0 views
  • 19 Sep, 2022
  • 4 locations